Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Hallmarks of improved immunological responses in the vaccination of more physically active elderly females.

Wong GCL, Narang V, Lu Y, Camous X, Nyunt MSZ, Carre C, Tan C, Xian CH, Chong J, Chua M, How W, Mok E, Tambyah P, Poidinger M, Abel B, Burdin N, Quemeneur L, Bosco N, Ng TP, Larbi A.

Exerc Immunol Rev. 2019;25:20-33.

2.

RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types.

Monaco G, Lee B, Xu W, Mustafah S, Hwang YY, Carré C, Burdin N, Visan L, Ceccarelli M, Poidinger M, Zippelius A, Pedro de Magalhães J, Larbi A.

Cell Rep. 2019 Feb 5;26(6):1627-1640.e7. doi: 10.1016/j.celrep.2019.01.041.

3.

Healthy elderly Singaporeans show no age-related humoral hyporesponsiveness nor diminished plasmablast generation in response to influenza vaccine.

Camous X, Visan L, Ying CTT, Abel B, Nyunt MSZ, Narang V, Poidinger M, Carre C, Sesay S, Bosco N, Burdin N, Tambyah PA, Pin NT, Larbi A.

Immun Ageing. 2018 Nov 12;15:28. doi: 10.1186/s12979-018-0137-4. eCollection 2018.

4.

Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.

Narang V, Lu Y, Tan C, Camous XFN, Nyunt SZ, Carre C, Mok EWH, Wong G, Maurer-Stroh S, Abel B, Burdin N, Poidinger M, Tambyah PA, Bosco N, Visan L, Ng TP, Larbi A.

Front Immunol. 2018 Oct 24;9:2465. doi: 10.3389/fimmu.2018.02465. eCollection 2018.

5.

Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine.

Giel-Moloney M, Goncalvez AP, Catalan J, Lecouturier V, Girerd-Chambaz Y, Diaz F, Maldonado-Arocho F, Gomila RC, Bernard MC, Oomen R, Delagrave S, Burdin N, Kleanthous H, Jackson N, Heinrichs J, Pugachev KV.

Sci Rep. 2018 Sep 4;8(1):13206. doi: 10.1038/s41598-018-31375-9.

6.

Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey.

Ravel G, Mantel N, Silvano J, Rogue A, Guy B, Jackson N, Burdin N.

Vaccine. 2017 Oct 13;35(43):5918-5923. doi: 10.1016/j.vaccine.2017.08.071. Epub 2017 Sep 4.

PMID:
28882438
7.

What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.

Burdin N, Handy LK, Plotkin SA.

Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12). pii: a029454. doi: 10.1101/cshperspect.a029454. Review.

PMID:
28289064
8.

Lessons from NK Cell Deficiencies in the Mouse.

Deauvieau F, Fenis A, Dalençon F, Burdin N, Vivier E, Kerdiles Y.

Curr Top Microbiol Immunol. 2016;395:173-90. doi: 10.1007/82_2015_473. Review.

PMID:
26385768
9.

Design and preclinical characterization of a novel vaccine adjuvant formulation consisting of a synthetic TLR4 agonist in a thermoreversible squalene emulsion.

Haensler J, Probeck P, Su J, Piras F, Dalençon F, Cotte JF, Chambon V, Iqbal SM, Hawkins L, Burdin N.

Int J Pharm. 2015;486(1-2):99-111. doi: 10.1016/j.ijpharm.2015.03.028. Epub 2015 Mar 17.

PMID:
25794609
10.

Cross-serotype immunity induced by immunization with a conserved rhinovirus capsid protein.

Glanville N, McLean GR, Guy B, Lecouturier V, Berry C, Girerd Y, Gregoire C, Walton RP, Pearson RM, Kebadze T, Burdin N, Bartlett NW, Almond JW, Johnston SL.

PLoS Pathog. 2013;9(9):e1003669. doi: 10.1371/journal.ppat.1003669. Epub 2013 Sep 26.

11.

HLA-DR and HLA-DP restricted epitopes from human cytomegalovirus glycoprotein B recognized by CD4+ T-cell clones from chronically infected individuals.

Ventura C, Bisceglia H, Girerd-Chambaz Y, Burdin N, Chaux P.

J Clin Immunol. 2012 Dec;32(6):1305-16. doi: 10.1007/s10875-012-9732-x. Epub 2012 Jul 15.

12.

Toll-like receptor agonists allow generation of long-lasting antipneumococcal humoral immunity in response to a plain polysaccharidic vaccine.

Taillardet M, Haffar G, Mondière P, Asensio MJ, Pléau-Pison T, Burdin N, Defrance T, Genestier L.

J Infect Dis. 2010 Aug 15;202(3):470-9. doi: 10.1086/653739.

PMID:
20575660
13.

Meningococcal serogroup C polysaccharide specific memory B cells, directly enumerated by labeled polysaccharide, are not affected by age at vaccination.

Henneken M, Burdin N, Thoroddsen E, Sigurdardottir ST, Trannoy E, Jonsdottir I.

Vaccine. 2010 Feb 25;28(9):2097-103. doi: 10.1016/j.vaccine.2009.12.039. Epub 2010 Jan 5.

PMID:
20056181
14.

Memory B and T cell responses induced by serotype 4 Streptococcus pneumoniae vaccines: longitudinal analysis comparing responses elicited by free polysaccharide, conjugate and carrier.

Deauvieau F, Dussurgey S, Rossignol D, de Montfort A, Burdin N, Guy B.

Vaccine. 2009 Dec 11;28(2):576-82. doi: 10.1016/j.vaccine.2009.09.081. Epub 2009 Oct 28.

PMID:
19878751
15.

The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells.

Taillardet M, Haffar G, Mondière P, Asensio MJ, Gheit H, Burdin N, Defrance T, Genestier L.

Blood. 2009 Nov 12;114(20):4432-40. doi: 10.1182/blood-2009-01-200014. Epub 2009 Sep 18.

16.

Evaluation of interferences between dengue vaccine serotypes in a monkey model.

Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, Jourdier TM, Ramirez L, Gregoire V, Charnay C, Burdin N, Dumas R, Lang J.

Am J Trop Med Hyg. 2009 Feb;80(2):302-11.

PMID:
19190230
17.

Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells.

Harenberg A, Guillaume F, Ryan EJ, Burdin N, Spada F.

Vaccine. 2008 Sep 15;26(39):5004-13. doi: 10.1016/j.vaccine.2008.07.050. Epub 2008 Aug 6.

PMID:
18691624
18.

The Canarypox-virus vaccine vector ALVAC triggers the release of IFN-gamma by Natural Killer (NK) cells enhancing Th1 polarization.

Ryan EJ, Harenberg A, Burdin N.

Vaccine. 2007 Apr 30;25(17):3380-90. Epub 2007 Jan 17.

PMID:
17234309
19.

New adjuvants for parenteral and mucosal vaccines.

Guy B, Burdin N.

Therapie. 2005 May-Jun;60(3):235-41. Review.

PMID:
16128265
20.

Immunological foundations to the quest for new vaccine adjuvants.

Burdin N, Guy B, Moingeon P.

BioDrugs. 2004;18(2):79-93. Review.

PMID:
15046524
21.

How microarrays can improve our understanding of immune responses and vaccine development.

Aujame L, Burdin N, Vicari M.

Ann N Y Acad Sci. 2002 Dec;975:1-23. Review. No abstract available.

PMID:
12538150
23.

Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223).

Andreae S, Piras F, Burdin N, Triebel F.

J Immunol. 2002 Apr 15;168(8):3874-80.

24.

Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis.

Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, Koezuka Y, Kumar V.

J Exp Med. 2001 Dec 17;194(12):1789-99.

25.

Cancer vaccines based on dendritic cells loaded with tumor-associated antigens.

Burdin N, Moingeon P.

Cell Biol Toxicol. 2001;17(2):67-75. Review.

PMID:
11499697
26.

Structural requirements for antigen presentation by mouse CD1.

Burdin N, Brossay L, Degano M, Iijima H, Gui M, Wilson IA, Kronenberg M.

Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10156-61.

27.

Membrane lymphotoxin is required for the development of different subpopulations of NK T cells.

Elewaut D, Brossay L, Santee SM, Naidenko OV, Burdin N, De Winter H, Matsuda J, Ware CF, Cheroutre H, Kronenberg M.

J Immunol. 2000 Jul 15;165(2):671-9.

28.

Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.

Singh N, Hong S, Scherer DC, Serizawa I, Burdin N, Kronenberg M, Koezuka Y, Van Kaer L.

J Immunol. 1999 Sep 1;163(5):2373-7.

29.
30.

CD1-mediated immune responses to glycolipids.

Burdin N, Kronenberg M.

Curr Opin Immunol. 1999 Jun;11(3):326-31. Review.

PMID:
10375559
32.

Presentation of peptide antigens by mouse CD1 requires endosomal localization and protein antigen processing.

Tangri S, Brossay L, Burdin N, Lee DJ, Corr M, Kronenberg M.

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14314-9.

33.

Structural requirements for galactosylceramide recognition by CD1-restricted NK T cells.

Brossay L, Naidenko O, Burdin N, Matsuda J, Sakai T, Kronenberg M.

J Immunol. 1998 Nov 15;161(10):5124-8.

34.

CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution.

Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, Kronenberg M.

J Exp Med. 1998 Oct 19;188(8):1521-8.

35.

Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.

Burdin N, Brossay L, Koezuka Y, Smiley ST, Grusby MJ, Gui M, Taniguchi M, Hayakawa K, Kronenberg M.

J Immunol. 1998 Oct 1;161(7):3271-81.

36.

Antigen-presenting function of mouse CD1: one molecule with two different kinds of antigenic ligands.

Brossay L, Burdin N, Tangri S, Kronenberg M.

Immunol Rev. 1998 Jun;163:139-50. Review.

PMID:
9700507
37.

Mouse CD1 is mainly expressed on hemopoietic-derived cells.

Brossay L, Jullien D, Cardell S, Sydora BC, Burdin N, Modlin RL, Kronenberg M.

J Immunol. 1997 Aug 1;159(3):1216-24.

PMID:
9233616
38.

Positive and negative selection of human B lymphocytes in vitro.

Banchereau J, Galibert L, Arpin C, Burdin N, Liu YJ, Garrone P.

Ann N Y Acad Sci. 1997 Apr 5;815:237-45. Review. No abstract available.

PMID:
9186660
39.

B-cell-derived IL-10: production and function.

Burdin N, Rousset F, Banchereau J.

Methods. 1997 Jan;11(1):98-111.

PMID:
8990095
40.

Inability to produce IL-6 is a functional feature of human germinal center B lymphocytes.

Burdin N, Galibert L, Garrone P, Durand I, Banchereau J, Rousset F.

J Immunol. 1996 Jun 1;156(11):4107-13.

PMID:
8666776
41.

Negative selection of human germinal center B cells by prolonged BCR cross-linking.

Galibert L, Burdin N, Barthélémy C, Meffre G, Durand I, Garcia E, Garrone P, Rousset F, Banchereau J, Liu YJ.

J Exp Med. 1996 May 1;183(5):2075-85.

42.

CD40 and B cell antigen receptor dual triggering of resting B lymphocytes turns on a partial germinal center phenotype.

Galibert L, Burdin N, de Saint-Vis B, Garrone P, Van Kooten C, Banchereau J, Rousset F.

J Exp Med. 1996 Jan 1;183(1):77-85.

43.

Presence of Epstein-Barr virus viral interleukin-10 in the serum of patients with non-human-immunodeficiency-virus-related diffuse large-cell non-Hodgkin's lymphomas.

Blay JY, Voorzanger N, Favrot M, Burdin N, Rousset F, Banchereau J.

Blood. 1995 Dec 15;86(12):4702-4. No abstract available.

44.

Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes.

Burdin N, Van Kooten C, Galibert L, Abrams JS, Wijdenes J, Banchereau J, Rousset F.

J Immunol. 1995 Mar 15;154(6):2533-44.

PMID:
7533177
45.

Functional CD40 antigen on B cells, dendritic cells and fibroblasts.

Banchereau J, Dubois B, Fayette J, Burdin N, Brière F, Miossec P, Rissoan MC, van Kooten C, Caux C.

Adv Exp Med Biol. 1995;378:79-83. No abstract available.

PMID:
8526150
46.

Immunologic and biochemical alterations in severe falciparum malaria: relation to neurological symptoms and outcome.

Deloron P, Dumont N, Nyongabo T, Aubry P, Astagneau P, Ndarugirire F, Menetrier-Caux C, Burdin N, Brelivet JC, Peyron F.

Clin Infect Dis. 1994 Sep;19(3):480-5.

PMID:
7811867
47.

Functional CD40 on B lymphocytes and dendritic cells.

Caux C, Burdin N, Galibert L, Hermann P, Renard N, Servet-Delprat C, Banchereau J.

Res Immunol. 1994 Mar-Apr;145(3):235-9; discussion 244-9. Review. No abstract available.

PMID:
7527581
48.

High levels of circulating IL-10 in human malaria.

Peyron F, Burdin N, Ringwald P, Vuillez JP, Rousset F, Banchereau J.

Clin Exp Immunol. 1994 Feb;95(2):300-3.

49.

Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor.

Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, Banchereau J, Favrot MC.

Blood. 1993 Oct 1;82(7):2169-74.

50.

Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10.

Burdin N, Péronne C, Banchereau J, Rousset F.

J Exp Med. 1993 Feb 1;177(2):295-304.

Supplemental Content

Loading ...
Support Center